amendment2023-09-21active
Arzneimittel-Richtlinie/ Anlage XII: Ravulizumab (Neues Anwendungsgebiet: Myasthenia gravis, AChR-Antikörper+) – Änderung der Angaben zur Geltungsdauer
Open official decision page ↗
G-BA source · retrieved 2026-08-05
Decision orientation
What the G-BA did
3 cited claims
Each claim links to the official G-BA page or an exact PDF page range.
Official metadata
- Decision date
- 2023-09-21
- Effective
- 21.09.2023
- Action type
- amendment
- Committee
- Arzneimittel
Case context
Listed normative targets
directiveArzneimittel-Richtlinie
directive annexAnlage XII: Nutzenbewertung nach § 35a SGB V
A listed target is not treated as a new directive version unless an official version source exists.
Official document package